Skip to Main Content

K. Wong, et al. Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cell Therapy Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment. Presented at The Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting, November 9-14, 2020.